Aktis Oncology, Inc. Stock-Based Compensation
Aktis Oncology, Inc. (AKTS) reported Stock-Based Compensation of $3.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Aktis Oncology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.22M, a 112.25% increase year-over-year.
- Aktis Oncology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.02M, a 144.70% increase year-over-year.
- Aktis Oncology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was $1.52M.
- Aktis Oncology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-03-31 was $1.24M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month |
|---|---|---|
| 2026-06-30 | $3.22M 10-Q · filed 2026-08-13 | $6.24M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $3.02M 10-Q · filed 2026-05-11 | |
| 2025-06-30 | $1.52M 10-Q · filed 2026-08-13 | $2.75M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $1.24M 10-Q · filed 2026-05-11 |